Management of Treatment-Resistant Psychosis

Initial Assessment and Switching Strategy

The American College of Psychiatry recommends switching to a different antipsychotic with a distinct pharmacodynamic profile, such as amisulpride, risperidone, paliperidone, or olanzapine, if quetiapine monotherapy fails after at least 4 weeks at therapeutic doses (300-400 mg/day) 1
Confirm adequate dosing and duration of quetiapine, requiring 300-400 mg/day for optimal efficacy, and at least 4 weeks at therapeutic dose to assess response 1
Verify medication adherence, as non-adherence is a common cause of apparent treatment failure 2

Switch to amisulpride, particularly effective for negative symptoms at low doses (50 mg twice daily), or risperidone/paliperidone for robust efficacy for positive symptoms 1
Olanzapine with concurrent metformin is highly effective but requires metabolic protection, starting metformin 500 mg daily and increasing to 1g twice daily as tolerated 1

If positive symptoms remain significant after a second antipsychotic trial, initiate clozapine, starting concurrent metformin to attenuate weight gain 1
Titrate clozapine to achieve plasma levels of at least 350 ng/mL, and consider increasing to 350-550 ng/mL if inadequate response after 12 weeks 1, 3

Obtain baseline measurements, including BMI, waist circumference, blood pressure, HbA1c, fasting glucose, lipid panel, prolactin, liver function tests, renal function, CBC, and ECG, before switching antipsychotics 3, 5
Monitor weekly for 6 weeks and repeat all measures at 3 months and annually thereafter 3, 2